Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Harvard Business School
Medtronic
Moodys
Baxter

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

SOLOSEC Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Solosec patents expire, and what generic alternatives are available?

Solosec is a drug marketed by Lupin and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in five countries.

The generic ingredient in SOLOSEC is secnidazole. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the secnidazole profile page.

Summary for SOLOSEC
Drug patent expirations by year for SOLOSEC
Drug Prices for SOLOSEC

See drug prices for SOLOSEC

Generic Entry Opportunity Date for SOLOSEC
Generic Entry Date for SOLOSEC*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
NDA:
Dosage:
GRANULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SOLOSEC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lupin Research IncPhase 3
Lupin Research IncPhase 4

See all SOLOSEC clinical trials

Synonyms for SOLOSEC
(RS)-1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol
1-(2- hydroxypropyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxypropyl)-2-methyl-5-nitroimidazol
1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol
1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2- ol
1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
1-(2-Methyl-5-nitro-imidazol-1-yl)-propan-2-ol
1-(2-methyl-5-nitro-imidazol-1-yl)propan-2-ol
1-(2-Methyl-5-nitroimidazol-1-yl)-2-propanol
1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
1-(2'-hydroxypropyl)-2-methyl-5- nitroimidazole
14,539 RP
1H-Imidazole-1-ethanol, a,2-dimethyl-5-nitro-
3366-95-8
366S958
A821901
AB0013222
AB00456738_16
AB00456738_17
AB00456738-13
AB00456738-15
AB1004868
AC-12065
AC1L2GUM
AC1Q2098
AK163575
AKOS005512552
AKOS025149490
alpha,2-Dimethyl-5-nitro-1H-imidazole-1-ethanol
alpha,2-Dimethyl-5-nitroimidazole-1-ethanol
ANW-41634
BBL010784
BCP12459
BDBM50349330
BRD-A70083328-001-02-9
BRD-A70083328-001-12-8
BSPBio_003556
CAS-3366-95-8
CCG-100896
CCG-39993
CHEBI:140628
CHEBI:94433
CHEMBL498847
CPD000149359
CS-4641
CTK8B3024
D07353
DB-000688
DB12834
DSSTox_CID_25934
DSSTox_GSID_45934
DSSTox_RID_81233
DTXSID3045934
EINECS 222-134-0
Flagentyl
FT-0601624
H737
HMS1922B12
HMS2051C20
HMS2090N15
HMS2231G11
HMS3369N08
HMS3393C20
HMS3656G14
HMS3714I05
HY-B1118
I06-0707
Imidazole-1-ethanol, alpha,2-dimethyl-5-nitro-
J-019291
J10074
KBio3_002874
KS-00000H1U
KS-1191
LS-174427
M-2516
MCULE-8220679702
MLS000559043
MLS000759496
MLS001201813
MLS001424126
MLS006011434
MolPort-000-811-111
NC00146
NCGC00095158-01
NCGC00095158-02
NCGC00095158-03
NCGC00095158-04
NCGC00095158-05
NSC-759812
NSC759812
Opera_ID_1811
Pharmakon1600-01505304
PM 185184
PM 185184, RP 14539
PM 185184; RP 14539; Sindose; Secnil
PM-185184
RP 14539
RP-14539
S0911
S2537
SAM001246716
SB19197
SBI-0207037.P001
SC-50820
SCHEMBL363924
Secnidal (TN)
Secnidazol
Secnidazol [INN-Spanish]
Secnidazole
Secnidazole (Flagentyl)
Secnidazole (USAN/INN)
Secnidazole [INN:BAN:DCF]
Secnidazole [USAN:INN:BAN:DCF]
Secnidazole hemihydrate
Secnidazolum
Secnidazolum [INN-Latin]
Secnil
Sindose
SMR000149359
Solosec (TN)
SPBio_000125
SPECTRUM1505304
Spectrum2_000033
Spectrum3_001956
SR-01000685111
SR-01000685111-4
SR-01000685111-6
SR-01000685111-7
STK590474
SW197526-3
SYM 1219
SYM-1219
Tox21_111457
Tox21_111457_1
VA11736

US Patents and Regulatory Information for SOLOSEC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin SOLOSEC secnidazole GRANULE;ORAL 209363-001 Sep 15, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lupin SOLOSEC secnidazole GRANULE;ORAL 209363-001 Sep 15, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lupin SOLOSEC secnidazole GRANULE;ORAL 209363-001 Sep 15, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
AstraZeneca
McKesson
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.